NYXH
$3.08-0.01 (-0.32%)
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA).
Recent News
Nyxoah Details Early U.S. Genio Launch, Reimbursement Update at Oppenheimer MedTech Conference 2026
Nyxoah (NASDAQ:NYXH) used its presentation at Oppenheimer’s MedTech and Services Conference 2026 to outline the company’s early U.S. launch progress for its Genio system, a neuromodulation therapy for obstructive sleep apnea (OSA), and to address investor questions around reimbursement and operating
Nyxoah SA (NYXH) Q4 2025 Earnings Call Highlights: U.S. Launch Success and Financial Challenges
Nyxoah SA (NYXH) reports strong U.S. launch momentum for Genio despite increased operating losses and cash burn concerns.
Nyxoah (NYXH) Q4 2025 Earnings Call Transcript
During the call, we will discuss our operating activities and review our fourth quarter 2025 financial results released after U.S. market close today, after which we will host a question and answer session. Before we begin, I would like to remind you that any statements that relate to expectations or predictions of future events, market trends, results, or performance are forward-looking statements. All forward-looking statements are based upon our current estimates and various assumptions.
Nyxoah Q4 Earnings Call Highlights
Nyxoah (NASDAQ:NYXH) used its fourth-quarter and full-year 2025 earnings call to outline the first results from the U.S. launch of its Genio hypoglossal nerve stimulation system, discuss the evolving reimbursement environment for the category, and provide initial growth expectations for early 2026.
Nyxoah SA (NYXH) Reports Q4 Loss, Misses Revenue Estimates
Nyxoah (NYXH) delivered earnings and revenue surprises of -4.62% and -2.46%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?